The CGSI analyst calls attention to HYP’s pipeline of products undergoing registration across its operating regions, which already enjoy “sizeable” sales in existing markets. “We see greater potential for HYP to grow its revenue after the products are launched. Management has shared that product registration typically takes 12 to 24 months, depending on the country and type of product.”
Hyphens Pharma International (HYP) has a “healthy pipeline” of products to support patmi growth ahead, says CGS International (CGSI) analyst Tay Wee Kuang.
“HYP’s positive revenue momentum was a confluence of organic growth from new products and stock-keeping units launched across its specialty pharmaceuticals and proprietary brands portfolio over time,” writes Tay in a Sept 11 note.
